Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:04 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableTerminatedINTERVENTIONAL

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

ClinicalTrials.gov · NCT06074055 · Registry updated: 2025-02-07

Condition / research focus: Infertility, Female
Sponsor: Reproductive Medicine Associates of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2023-10-25. Completion: 2024-10-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FET Protocol (other)

Where the study takes place — 2 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Reproductive Medicine Associates of New Jersey
Basking Ridge, New Jersey, United States
Site recruitment: Not reported
Reproductive Medicine Associates of New Jersey
Marlton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Influence of Sperm Morphology and Functional Indices on Blastocyst Development in Assisted Reproduction

ClinicalTrials.gov · NCT06801652 · Registry updated: 2025-01-30

Condition / research focus: Spermatozoa, Abnormal; in Vitro Fertilization; Blastocyst; Aneuploidy
Sponsor: Calla IVF Center
Countries with listed sites: Romania
Registry dates and results: Start: 2023-10-21. Completion: 2024-11-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sperm morphology indexes (other)

Where the study takes place — 1 listed sites

Calla Ivf Center
Oradea, Bihor County, Romania
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

ClinicalTrials.gov · NCT05286554 · Registry updated: 2025-01-29

Condition / research focus: Female Infertility
Sponsor: Alexandria University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-03-17. Completion: 2024-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

gonadotropin releasing hormone-agonist (drug) — also listed as: triptorelin 0.1 mg
Progesterone (drug) — also listed as: cyclogest

Where the study takes place — 1 listed sites

Alexandria University
Alexandria, Alexandria Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

ClinicalTrials.gov · NCT06608186 · Registry updated: 2025-01-22

Condition / research focus: PCOS (Polycystic Ovary Syndrome)
Sponsor: Ahmed Saad
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-10-01. Completion: 2025-01-19 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix drug (drug) — also listed as: cetrorelix
Drospirenone drug (drug)

Where the study takes place — 1 listed sites

Hawaa Fertility center
Banhā, Qalyubia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Laparoscopic Ventral Hernia Repair with Routine Defect Closure Using Su2ura® Approximation Device

ClinicalTrials.gov · NCT04986917 · Registry updated: 2025-01-21

Condition / research focus: Ventral Hernia
Sponsor: Anchora Medical
Countries with listed sites: Israel
Registry dates and results: Start: 2022-01-19. Completion: 2024-11-21 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hernia repair surgery using the Su2ura® approximation device (device) — also listed as: study device intervention
Physical Examination (diagnostic_test)
Vital Signs (diagnostic_test)
Blood Tests (diagnostic_test)
Urine Pregnancy Test (diagnostic_test)
Abdominal Ultrasound imaging (diagnostic_test)
EuraHS-QoL (other) — also listed as: (hernia-specific European Hernia Society Quality of Life Questionnaire)
Visual Analouge Scale (VAS) (other)
Clinical evaluation for hernia recurrence and clinical bulging (diagnostic_test)

Where the study takes place — 2 listed sites

Hillel Yaffe Medical Center
Hadera, Central District, Israel
Site recruitment: Not reported
Barzilai Medical Center
Ashkelon, Southern District, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders

ClinicalTrials.gov · NCT06778733 · Registry updated: 2025-01-16

Condition / research focus: Female Infertility
Sponsor: University of Athens
Countries with listed sites: Greece
Registry dates and results: Start: 2022-01-01. Completion: 2024-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clomiphane citrate (drug) — also listed as: Clomiphene citrate 50mg/tab, Serpafar 50mg/tab
recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (drug) — also listed as: Gonal-f 150 Iu/day, Gonal-f 300 IU/day

Where the study takes place — 2 listed sites

Aretaieion University Hospital
Athens, Attica, Greece
Site recruitment: Not reported
Aretaieion University Hospital
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells

ClinicalTrials.gov · NCT05330130 · Registry updated: 2025-01-09

Condition / research focus: Ovarian Function Insufficiency; Fertility Issues; Infertility,Female; Infertility
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-07-05. Completion: 2024-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follitropin beta injection 150 IU (drug) — also listed as: FOLLISTIM AQ
Follitropin beta injection 300 IU (drug) — also listed as: FOLLISTIM AQ

Where the study takes place — 1 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support

ClinicalTrials.gov · NCT05969795 · Registry updated: 2025-01-09

Condition / research focus: Pregnancy Related; Infertility, Female
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-09-05. Completion: 2026-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Transvaginal ultrasound (diagnostic_test)
Serial serum LH, E2, P4 (diagnostic_test)
Progesterone 100 Mg Vaginal Insert (drug) — also listed as: Progesterone 100Mg Vag Tab
Serum P4 day of ET - Control Group (diagnostic_test)
Serum P4 day of ET - Study Group (diagnostic_test)
Embryo transfer (procedure) — also listed as: ET
Serum hCG 10 days after ET (diagnostic_test)
Serum P4 10 days after ET (diagnostic_test)

Where the study takes place — 3 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Recruiting
ART Fertility Clinics Al Ain
Al Ain City, United Arab Emirates
Site recruitment: Recruiting
ART Fertility Clinics Dubai
Dubai, United Arab Emirates
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

ClinicalTrials.gov · NCT06333691 · Registry updated: 2025-01-07

Condition / research focus: Ovarian Hyperstimulation Syndrome
Sponsor: Minia University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-10-01. Completion: 2024-02-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Calcium Gluconate (drug) — also listed as: Cabergoline, Diosmin

Where the study takes place — 1 listed sites

Minia University, Faculty of Pharmacy
Minya, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Estradiol and Progesterone Levels Following Frozen Embryo Transfer

ClinicalTrials.gov · NCT04997525 · Registry updated: 2025-01-03

Condition / research focus: Infertility
Sponsor: Copenhagen University Hospital at Herlev
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-04-20. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Estradiol Tablets (drug)
Progesterone (drug)
Follitropin Alfa (drug)
Chorionic Gonadotropin, Alpha (drug)

Where the study takes place — 1 listed sites

Herlev University Hospital
Herlev, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Community-based Provision of Urine Pregnancy Tests as Linkage to Reproductive Health Services

ClinicalTrials.gov · NCT03626597 · Registry updated: 2024-12-17

Condition / research focus: Prenatal Care Late; Contraceptive Usage; Pregnancy Complication
Sponsor: Indiana University
Countries with listed sites: Kenya
Registry dates and results: Start: 2018-10-13. Completion: 2019-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Urine Pregnancy Test (diagnostic_test)
CHV-based post-test counseling & referral (behavioral)
Phone-based post-test counseling & referral (behavioral)

Where the study takes place — 1 listed sites

Moi University/MTRH
Eldoret, Kenya
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

ClinicalTrials.gov · NCT04489134 · Registry updated: 2024-12-11

Condition / research focus: Pharmacokinetics
Sponsor: Rennes University Hospital
Countries with listed sites: France
Registry dates and results: Start: 2022-02-15. Completion: 2023-05-16 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Treatment A (drug)
Treatment B (drug)
Treament C (drug)
Treatment D (drug)
Pharmacocinetik (biological)
Genetic (genetic)
Selection visit: (other)

Where the study takes place — 1 listed sites

CHU de Rennes
Rennes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

ClinicalTrials.gov · NCT03064074 · Registry updated: 2024-12-04

Condition / research focus: Osteogenesis Imperfecta
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2017-11-15. Completion: 2022-07-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fresolimumab (drug)

Where the study takes place — 2 listed sites

Oregon Health Science University
Portland, Oregon, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

ClinicalTrials.gov · NCT06091436 · Registry updated: 2024-12-03

Condition / research focus: Infertility
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-03-24. Completion: 2024-01-29 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GenSci094 (drug)
Placebo RecFSH / follitropin alfa (drug)
Biological: RecFSH / Follitropin alfa (Days 1 to 7) (biological)
Placebo GenSci094 (drug)
RecFSH / Follitropin alfa (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (drug)

Where the study takes place — 1 listed sites

The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

ClinicalTrials.gov · NCT05720702 · Registry updated: 2024-11-27

Condition / research focus: NAFLD
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-30. Completion: 2024-08-23 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

homocysteine (Hcy) lowering supplements (dietary_supplement)

Where the study takes place — 1 listed sites

Duke University
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Embryo Developmental Potential in a Novel 2-step IVM System

ClinicalTrials.gov · NCT04285892 · Registry updated: 2024-11-25

Condition / research focus: In Vitro Maturation of Oocytes
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2020-07-16. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CAPA-IVM (device)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?

ClinicalTrials.gov · NCT02571543 · Registry updated: 2024-11-19

Condition / research focus: Ovulation; Ovulation Inhibition; Ovulation Inhibition/Drug Effects; Pregnancy; Fertilization in Vitro/Methods
Sponsor: Insel Gruppe AG, University Hospital Bern
Countries with listed sites: Switzerland
Registry dates and results: Start: 2016-01. Completion: 2022-08-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ibuprofen (drug) — also listed as: Brufen®

Where the study takes place — 1 listed sites

Department of Obstetrics and Gynecology, Bern University Hospital
Bern, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Calciotropic Effects After HCG Stimulation Test

ClinicalTrials.gov · NCT03254641 · Registry updated: 2024-11-15

Condition / research focus: Hypogonadism, Male
Sponsor: Martin Blomberg Jensen
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-04-01. Completion: 2021-10-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: hCG

Where the study takes place — 2 listed sites

Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

ClinicalTrials.gov · NCT06676410 · Registry updated: 2024-11-06

Condition / research focus: HIV; HIV Infection
Sponsor: Code Pharma
Countries with listed sites: Brazil
Registry dates and results: Start: 2023-07-20. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (22)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ICF (other)
Eligibility Assessment (behavioral)
Demographic data (other)
Weight, height and BMI (diagnostic_test)
Vital Signs (other)
Medical evaluation (diagnostic_test)
Safety exam (diagnostic_test)
Pregnancy test (diagnostic_test)
Serology (diagnostic_test)
Randomization (other)
Apoptosis markers (diagnostic_test)
Cell activation markers (diagnostic_test)
Inflammation markers (diagnostic_test)
Proviral DNA: (diagnostic_test)
HIV-specific antibodies (diagnostic_test)
HIV viral load (RNA) (diagnostic_test)
Codivir® Training (behavioral)
Dispensing Codivir® (drug)
Codivir® Accounting (other)
Concomitant medication (other)
Adverse events (other)
Antiretrovirals (drug)

Where the study takes place — 1 listed sites

RDSS Research Center
São Paulo, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Injection Free IVF

ClinicalTrials.gov · NCT04850261 · Registry updated: 2024-10-30

Condition / research focus: Fertility Disorders
Sponsor: Insel Gruppe AG, University Hospital Bern
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-05-01. Completion: 2024-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG Injection (drug)
Nafarelin nasal spray (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:04 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableTerminatedINTERVENTIONAL

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

ClinicalTrials.gov · NCT06074055 · Registry updated: 2025-02-07

Condition / research focus: Infertility, Female
Sponsor: Reproductive Medicine Associates of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2023-10-25. Completion: 2024-10-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FET Protocol (other)

Where the study takes place — 2 listed sites

Reproductive Medicine Associates of New Jersey
Basking Ridge, New Jersey, United States
Site recruitment: Not reported
Reproductive Medicine Associates of New Jersey
Marlton, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Influence of Sperm Morphology and Functional Indices on Blastocyst Development in Assisted Reproduction

ClinicalTrials.gov · NCT06801652 · Registry updated: 2025-01-30

Condition / research focus: Spermatozoa, Abnormal; in Vitro Fertilization; Blastocyst; Aneuploidy
Sponsor: Calla IVF Center
Countries with listed sites: Romania
Registry dates and results: Start: 2023-10-21. Completion: 2024-11-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sperm morphology indexes (other)

Where the study takes place — 1 listed sites

Calla Ivf Center
Oradea, Bihor County, Romania
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

ClinicalTrials.gov · NCT05286554 · Registry updated: 2025-01-29

Condition / research focus: Female Infertility
Sponsor: Alexandria University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-03-17. Completion: 2024-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

gonadotropin releasing hormone-agonist (drug) — also listed as: triptorelin 0.1 mg
Progesterone (drug) — also listed as: cyclogest

Where the study takes place — 1 listed sites

Alexandria University
Alexandria, Alexandria Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

ClinicalTrials.gov · NCT06608186 · Registry updated: 2025-01-22

Condition / research focus: PCOS (Polycystic Ovary Syndrome)
Sponsor: Ahmed Saad
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-10-01. Completion: 2025-01-19 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix drug (drug) — also listed as: cetrorelix
Drospirenone drug (drug)

Where the study takes place — 1 listed sites

Hawaa Fertility center
Banhā, Qalyubia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Laparoscopic Ventral Hernia Repair with Routine Defect Closure Using Su2ura® Approximation Device

ClinicalTrials.gov · NCT04986917 · Registry updated: 2025-01-21

Condition / research focus: Ventral Hernia
Sponsor: Anchora Medical
Countries with listed sites: Israel
Registry dates and results: Start: 2022-01-19. Completion: 2024-11-21 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hernia repair surgery using the Su2ura® approximation device (device) — also listed as: study device intervention
Physical Examination (diagnostic_test)
Vital Signs (diagnostic_test)
Blood Tests (diagnostic_test)
Urine Pregnancy Test (diagnostic_test)
Abdominal Ultrasound imaging (diagnostic_test)
EuraHS-QoL (other) — also listed as: (hernia-specific European Hernia Society Quality of Life Questionnaire)
Visual Analouge Scale (VAS) (other)
Clinical evaluation for hernia recurrence and clinical bulging (diagnostic_test)

Where the study takes place — 2 listed sites

Hillel Yaffe Medical Center
Hadera, Central District, Israel
Site recruitment: Not reported
Barzilai Medical Center
Ashkelon, Southern District, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders

ClinicalTrials.gov · NCT06778733 · Registry updated: 2025-01-16

Condition / research focus: Female Infertility
Sponsor: University of Athens
Countries with listed sites: Greece
Registry dates and results: Start: 2022-01-01. Completion: 2024-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clomiphane citrate (drug) — also listed as: Clomiphene citrate 50mg/tab, Serpafar 50mg/tab
recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (drug) — also listed as: Gonal-f 150 Iu/day, Gonal-f 300 IU/day

Where the study takes place — 2 listed sites

Aretaieion University Hospital
Athens, Attica, Greece
Site recruitment: Not reported
Aretaieion University Hospital
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells

ClinicalTrials.gov · NCT05330130 · Registry updated: 2025-01-09

Condition / research focus: Ovarian Function Insufficiency; Fertility Issues; Infertility,Female; Infertility
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-07-05. Completion: 2024-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follitropin beta injection 150 IU (drug) — also listed as: FOLLISTIM AQ
Follitropin beta injection 300 IU (drug) — also listed as: FOLLISTIM AQ

Where the study takes place — 1 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support

ClinicalTrials.gov · NCT05969795 · Registry updated: 2025-01-09

Condition / research focus: Pregnancy Related; Infertility, Female
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-09-05. Completion: 2026-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Transvaginal ultrasound (diagnostic_test)
Serial serum LH, E2, P4 (diagnostic_test)
Progesterone 100 Mg Vaginal Insert (drug) — also listed as: Progesterone 100Mg Vag Tab
Serum P4 day of ET - Control Group (diagnostic_test)
Serum P4 day of ET - Study Group (diagnostic_test)
Embryo transfer (procedure) — also listed as: ET
Serum hCG 10 days after ET (diagnostic_test)
Serum P4 10 days after ET (diagnostic_test)

Where the study takes place — 3 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Recruiting
ART Fertility Clinics Al Ain
Al Ain City, United Arab Emirates
Site recruitment: Recruiting
ART Fertility Clinics Dubai
Dubai, United Arab Emirates
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

ClinicalTrials.gov · NCT06333691 · Registry updated: 2025-01-07

Condition / research focus: Ovarian Hyperstimulation Syndrome
Sponsor: Minia University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-10-01. Completion: 2024-02-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Calcium Gluconate (drug) — also listed as: Cabergoline, Diosmin

Where the study takes place — 1 listed sites

Minia University, Faculty of Pharmacy
Minya, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Estradiol and Progesterone Levels Following Frozen Embryo Transfer

ClinicalTrials.gov · NCT04997525 · Registry updated: 2025-01-03

Condition / research focus: Infertility
Sponsor: Copenhagen University Hospital at Herlev
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-04-20. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Estradiol Tablets (drug)
Progesterone (drug)
Follitropin Alfa (drug)
Chorionic Gonadotropin, Alpha (drug)

Where the study takes place — 1 listed sites

Herlev University Hospital
Herlev, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Community-based Provision of Urine Pregnancy Tests as Linkage to Reproductive Health Services

ClinicalTrials.gov · NCT03626597 · Registry updated: 2024-12-17

Condition / research focus: Prenatal Care Late; Contraceptive Usage; Pregnancy Complication
Sponsor: Indiana University
Countries with listed sites: Kenya
Registry dates and results: Start: 2018-10-13. Completion: 2019-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Urine Pregnancy Test (diagnostic_test)
CHV-based post-test counseling & referral (behavioral)
Phone-based post-test counseling & referral (behavioral)

Where the study takes place — 1 listed sites

Moi University/MTRH
Eldoret, Kenya
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

ClinicalTrials.gov · NCT04489134 · Registry updated: 2024-12-11

Condition / research focus: Pharmacokinetics
Sponsor: Rennes University Hospital
Countries with listed sites: France
Registry dates and results: Start: 2022-02-15. Completion: 2023-05-16 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Treatment A (drug)
Treatment B (drug)
Treament C (drug)
Treatment D (drug)
Pharmacocinetik (biological)
Genetic (genetic)
Selection visit: (other)

Where the study takes place — 1 listed sites

CHU de Rennes
Rennes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

ClinicalTrials.gov · NCT03064074 · Registry updated: 2024-12-04

Condition / research focus: Osteogenesis Imperfecta
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2017-11-15. Completion: 2022-07-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fresolimumab (drug)

Where the study takes place — 2 listed sites

Oregon Health Science University
Portland, Oregon, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

ClinicalTrials.gov · NCT06091436 · Registry updated: 2024-12-03

Condition / research focus: Infertility
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-03-24. Completion: 2024-01-29 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GenSci094 (drug)
Placebo RecFSH / follitropin alfa (drug)
Biological: RecFSH / Follitropin alfa (Days 1 to 7) (biological)
Placebo GenSci094 (drug)
RecFSH / Follitropin alfa (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (drug)

Where the study takes place — 1 listed sites

The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

ClinicalTrials.gov · NCT05720702 · Registry updated: 2024-11-27

Condition / research focus: NAFLD
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-30. Completion: 2024-08-23 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

homocysteine (Hcy) lowering supplements (dietary_supplement)

Where the study takes place — 1 listed sites

Duke University
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Embryo Developmental Potential in a Novel 2-step IVM System

ClinicalTrials.gov · NCT04285892 · Registry updated: 2024-11-25

Condition / research focus: In Vitro Maturation of Oocytes
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2020-07-16. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CAPA-IVM (device)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?

ClinicalTrials.gov · NCT02571543 · Registry updated: 2024-11-19

Condition / research focus: Ovulation; Ovulation Inhibition; Ovulation Inhibition/Drug Effects; Pregnancy; Fertilization in Vitro/Methods
Sponsor: Insel Gruppe AG, University Hospital Bern
Countries with listed sites: Switzerland
Registry dates and results: Start: 2016-01. Completion: 2022-08-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ibuprofen (drug) — also listed as: Brufen®

Where the study takes place — 1 listed sites

Department of Obstetrics and Gynecology, Bern University Hospital
Bern, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Calciotropic Effects After HCG Stimulation Test

ClinicalTrials.gov · NCT03254641 · Registry updated: 2024-11-15

Condition / research focus: Hypogonadism, Male
Sponsor: Martin Blomberg Jensen
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-04-01. Completion: 2021-10-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: hCG

Where the study takes place — 2 listed sites

Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

ClinicalTrials.gov · NCT06676410 · Registry updated: 2024-11-06

Condition / research focus: HIV; HIV Infection
Sponsor: Code Pharma
Countries with listed sites: Brazil
Registry dates and results: Start: 2023-07-20. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (22)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ICF (other)
Eligibility Assessment (behavioral)
Demographic data (other)
Weight, height and BMI (diagnostic_test)
Vital Signs (other)
Medical evaluation (diagnostic_test)
Safety exam (diagnostic_test)
Pregnancy test (diagnostic_test)
Serology (diagnostic_test)
Randomization (other)
Apoptosis markers (diagnostic_test)
Cell activation markers (diagnostic_test)
Inflammation markers (diagnostic_test)
Proviral DNA: (diagnostic_test)
HIV-specific antibodies (diagnostic_test)
HIV viral load (RNA) (diagnostic_test)
Codivir® Training (behavioral)
Dispensing Codivir® (drug)
Codivir® Accounting (other)
Concomitant medication (other)
Adverse events (other)
Antiretrovirals (drug)

Where the study takes place — 1 listed sites

RDSS Research Center
São Paulo, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Injection Free IVF

ClinicalTrials.gov · NCT04850261 · Registry updated: 2024-10-30

Condition / research focus: Fertility Disorders
Sponsor: Insel Gruppe AG, University Hospital Bern
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-05-01. Completion: 2024-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG Injection (drug)
Nafarelin nasal spray (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →